Copper-containing enzymes: Site types and low-molecular-weight model compounds

Tishchenko, K. I.; Белоглазкина, Е. К.; Мажуга, А. Г.; Зык, Н. В.

doi:10.1134/s2079978016010027

Cited by 24 publications

(16 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to MFCs, which have inherent drawbacks such as microbial contamination and uncontrollable microbial activity, EBFCs have been widely investigated for biomedical applications 6 . EBFCs can have different types of enzymes, such as cellobiose dehydrogenase (CDH), glucose dehydrogenase (GDH), and glucose oxidase (GOD) for the anode and laccase, ascorbate oxidase, copper-containing oxidase, and bilirubin oxidase (BOD) for the cathode [7][8][9][10][11][12][13] . Among these, GDH and GOD are commonly used in the biomedical field due to the relatively high glucose concentrations in living tissue compared to those of the other consumed components, which can generate a high current density 14,15 .…”

mentioning

confidence: 99%

Performance of a glucose-reactive enzyme-based biofuel cell system for biomedical applications

Jeon

Lee

Dashnyam

et al. 2019

Sci Rep

View full text Add to dashboard Cite

A glucose-reactive enzyme-based biofuel cell system (EBFC) was recently introduced in the scientific community for biomedical applications, such as implantable artificial organs and biosensors for drug delivery. Upon direct contact with tissues or organs, an implanted EBFC can exert effects that damage or stimulate intact tissue due to its byproducts or generated electrical cues, which have not been investigated in detail. Here, we perform a fundamental cell culture study using a glucose dehydrogenase (GDH) as an anode enzyme and bilirubin oxidase (BOD) as a cathode enzyme. The fabricated EBFC had power densities of 15.26 to 38.33 nW/cm 2 depending on the enzyme concentration in media supplemented with 25 mM glucose. Despite the low power density, the GDH-based EBFC showed increases in cell viability (~150%) and cell migration (~90%) with a relatively low inflammatory response. However, glucose oxidase (GOD), which has been used as an EBFC anode enzyme, revealed extreme cytotoxicity (~10%) due to the lethal concentration of H 2 o 2 byproducts (~1500 µM). Therefore, with its cytocompatibility and cell-stimulating effects, the GDH-based EBFC is considered a promising implantable tool for generating electricity for biomedical applications. Finally, the GDH-based EBFC can be used for introducing electricity during cell culture and the fabrication of organs on a chip and a power source for implantable devices such as biosensors, biopatches, and artificial organs.

show abstract

mentioning

confidence: 99%

Performance of a glucose-reactive enzyme-based biofuel cell system for biomedical applications

Jeon

Lee

Dashnyam

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Copper metal plays a vital role in biological activities and is an integral part of some enzymes in human body. [114] On the basis of biocompatibility of copper metal, its complexes can be better candidates for various applications including medicinal chemistry. Recent reports of copper, gold and silver complexes highlight their efficiency as anticancer agents.…”

Section: Coordination Compounds For Biological Applicationsmentioning

confidence: 99%

Pyridine Derivatives as Biologically Active Precursors; Organics and Selected Coordination Complexes

Khan

2021

ChemistrySelect

View full text Add to dashboard Cite

Pyridine (py) is an important heterocyclic compound and is an integral part of various natural products. There are various medicines containing py ring system being available in the market to combat different human ailments. Observing the medicine market, Omeprazole, a widely used py-based drug in medicinal market since 1998. Netupitant (an antiemitic drug, since 2014) is used in combination with another drug to prevent acute and delayed vomiting and nausea associated with cancer chemotherapy led the run towards development of anticancer drugs. Several drugs have been approved by FDA for the treatment of cancer in recent years such as, Abemaciclib (2015), Lorlatinib (2018), Apalutamide (2018) and Ivosidenib (2019). Research on py on the bases of these advancements is an evergreen field and associated with greater hopes to address several disease related issues. Several compounds are in the process of clinical trials and are expected to serve various purposes in days to come. This review article deals with recent findings in py chemistry and its coordination complexes. The medicinal efficiency has been argued for organic and inorganic derivatives. Selected biological applications are hereby discussed as follow up study of our report in 2015. Suitable literature prior to 2015 has also been incorporated in appropriate places in order to cover the scope in broader sense.

show abstract

“…These molecules are mercaptopurine, thioguanine, captopril, dimercaptopropanol, and dimercaptosuccinate. The quantified K i values were 18 (15), 35 (21), 46 (26), 16 (18), and 48 (37) µM for mercaptopurine, thioguanine, captopril, dimercaptopropanol, and dimercaptosuccinate, respectively, against the laccase of T. versicolor (A. oryzae) (Table 1 and Figure 3). To the best of our knowledge, these are the first organic small-molecule inhibitors of laccase.…”

Section: Enzyme-based Assays Identified New Organic Laccase Inhibitorsmentioning

confidence: 99%

“…DBH contains two copper-containing domains: CuH and CuM. Three histidines form a coordinated cluster with a copper atom in CuH, and CuM contains two histidines and one methionine, which coordinate with a copper atom [25,26].…”

Section: Introductionmentioning

confidence: 99%

New Inhibitors of Laccase and Tyrosinase by Examination of Cross-Inhibition between Copper-Containing Enzymes

Chaudhary

Chong

Neupane

et al. 2021

IJMS

View full text Add to dashboard Cite

Coppers play crucial roles in the maintenance homeostasis in living species. Approximately 20 enzyme families of eukaryotes and prokaryotes are known to utilize copper atoms for catalytic activities. However, small-molecule inhibitors directly targeting catalytic centers are rare, except for those that act against tyrosinase and dopamine-β-hydroxylase (DBH). This study tested whether known tyrosinase inhibitors can inhibit the copper-containing enzymes, ceruloplasmin, DBH, and laccase. While most small molecules minimally reduced the activities of ceruloplasmin and DBH, aside from known inhibitors, 5 of 28 tested molecules significantly inhibited the function of laccase, with the Ki values in the range of 15 to 48 µM. Enzyme inhibitory kinetics classified the molecules as competitive inhibitors, whereas differential scanning fluorimetry and fluorescence quenching supported direct bindings. To the best of our knowledge, this is the first report on organic small-molecule inhibitors for laccase. Comparison of tyrosinase and DBH inhibitors using cheminformatics predicted that the presence of thione moiety would suffice to inhibit tyrosinase. Enzyme assays confirmed this prediction, leading to the discovery of two new dual tyrosinase and DBH inhibitors.

show abstract

Copper-containing enzymes: Site types and low-molecular-weight model compounds

Cited by 24 publications

References 103 publications

Performance of a glucose-reactive enzyme-based biofuel cell system for biomedical applications

Performance of a glucose-reactive enzyme-based biofuel cell system for biomedical applications

Pyridine Derivatives as Biologically Active Precursors; Organics and Selected Coordination Complexes

New Inhibitors of Laccase and Tyrosinase by Examination of Cross-Inhibition between Copper-Containing Enzymes

Contact Info

Product

Resources

About